Shares in Morphosys AG surged by more than 17 percent during trading last week on news of a deal with Celgene Corp. for its anti-CD38 multiple myeloma antibody MOR202, worth an immediate €127 million (US$165.5 million) and which could be worth up to €628 million in total.